Selected research
Industry Research
Women's Health Drugs Industry Research Report 2026
Market perspective
The global Women's Health Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Women's Health Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Women's Health Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Women's Health Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Women's Health Drugs include Merck & Co., Pfizer, GlaxoSmithKline, Bayer AG, AbbVie Inc, Therapeutics MD and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Women's Health Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Women's Health Drugs Market by Company
Merck & Co.
Pfizer
GlaxoSmithKline
Bayer AG
AbbVie Inc
Therapeutics MD
Allergan Plc
Women's Health Drugs Segment by Type
Contraceptives Drug
Infertility Drug
Polycystic Ovary Syndrome Drug
Menopause Drug
Postmenopausal Osteoporosis Drug
Endometriosis Drug
Others
Women's Health Drugs Segment by Application
Elderly Women
Young Women
Little Girls
Women's Health Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Women's Health Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Women's Health Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Women's Health Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Women's Health Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Women's Health Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Women's Health Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Contraceptives Drug
- Infertility Drug
- Polycystic Ovary Syndrome Drug
- Menopause Drug
- Postmenopausal Osteoporosis Drug
- Endometriosis Drug
- Others
Applications
- Elderly Women
- Young Women
- Little Girls
Companies covered
- Merck & Co.
- Pfizer
- GlaxoSmithKline
- Bayer AG
- AbbVie Inc
- Therapeutics MD
- Allergan Plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Women's Health Drugs Market Size (2021-2032)
- 2.2.2 Global Women's Health Drugs Sales (2021-2032)
- 2.2.3 Global Women's Health Drugs Market Average Price (2021-2032)
- 2.3 Women's Health Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Contraceptives Drug
- 2.3.3 Infertility Drug
- 2.3.4 Polycystic Ovary Syndrome Drug
- 2.3.5 Menopause Drug
- 2.3.6 Postmenopausal Osteoporosis Drug
- 2.3.7 Endometriosis Drug
- 2.3.8 Others
- 2.4 Women's Health Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Elderly Women
- 2.4.3 Young Women
- 2.4.4 Little Girls
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Women's Health Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Women's Health Drugs Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Women's Health Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Women's Health Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Women's Health Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Women's Health Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Women's Health Drugs, Product Type & Application
- 3.8 Global Manufacturers of Women's Health Drugs, Established Date
- 3.9 Global Women's Health Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck & Co.
- 4.1.1 Merck & Co. Company Information
- 4.1.2 Merck & Co. Business Overview
- 4.1.3 Merck & Co. Women's Health Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck & Co. Women's Health Drugs Product Portfolio
- 4.1.5 Merck & Co. Recent Developments
- 4.2 Pfizer
- 4.2.1 Pfizer Company Information
- 4.2.2 Pfizer Business Overview
- 4.2.3 Pfizer Women's Health Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Pfizer Women's Health Drugs Product Portfolio
- 4.2.5 Pfizer Recent Developments
- 4.3 GlaxoSmithKline
- 4.3.1 GlaxoSmithKline Company Information
- 4.3.2 GlaxoSmithKline Business Overview
- 4.3.3 GlaxoSmithKline Women's Health Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 GlaxoSmithKline Women's Health Drugs Product Portfolio
- 4.3.5 GlaxoSmithKline Recent Developments
- 4.4 Bayer AG
- 4.4.1 Bayer AG Company Information
- 4.4.2 Bayer AG Business Overview
- 4.4.3 Bayer AG Women's Health Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bayer AG Women's Health Drugs Product Portfolio
- 4.4.5 Bayer AG Recent Developments
- 4.5 AbbVie Inc
- 4.5.1 AbbVie Inc Company Information
- 4.5.2 AbbVie Inc Business Overview
- 4.5.3 AbbVie Inc Women's Health Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AbbVie Inc Women's Health Drugs Product Portfolio
- 4.5.5 AbbVie Inc Recent Developments
- 4.6 Therapeutics MD
- 4.6.1 Therapeutics MD Company Information
- 4.6.2 Therapeutics MD Business Overview
- 4.6.3 Therapeutics MD Women's Health Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Therapeutics MD Women's Health Drugs Product Portfolio
- 4.6.5 Therapeutics MD Recent Developments
- 4.7 Allergan Plc
- 4.7.1 Allergan Plc Company Information
- 4.7.2 Allergan Plc Business Overview
- 4.7.3 Allergan Plc Women's Health Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Allergan Plc Women's Health Drugs Product Portfolio
- 4.7.5 Allergan Plc Recent Developments
5 Global Women's Health Drugs Market Scenario by Region
- 5.1 Global Women's Health Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Women's Health Drugs Sales by Region: 2021-2032
- 5.2.1 Global Women's Health Drugs Sales by Region: 2021-2026
- 5.2.2 Global Women's Health Drugs Sales by Region: 2027-2032
- 5.3 Global Women's Health Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Women's Health Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Women's Health Drugs Revenue by Region: 2027-2032
- 5.4 North America Women's Health Drugs Market Facts & Figures by Country
- 5.4.1 North America Women's Health Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Women's Health Drugs Sales by Country (2021-2032)
- 5.4.3 North America Women's Health Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Women's Health Drugs Market Facts & Figures by Country
- 5.5.1 Europe Women's Health Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Women's Health Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Women's Health Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Women's Health Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Women's Health Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Women's Health Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Women's Health Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Women's Health Drugs Market Facts & Figures by Country
- 5.7.1 South America Women's Health Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Women's Health Drugs Sales by Country (2021-2032)
- 5.7.3 South America Women's Health Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Women's Health Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Women's Health Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Women's Health Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Women's Health Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Women's Health Drugs Sales by Type (2021-2032)
- 6.1.1 Global Women's Health Drugs Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Women's Health Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Women's Health Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Women's Health Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Women's Health Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Women's Health Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Women's Health Drugs Sales by Application (2021-2032)
- 7.1.1 Global Women's Health Drugs Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Women's Health Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Women's Health Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Women's Health Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Women's Health Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Women's Health Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Women's Health Drugs Value Chain Analysis
- 8.1.1 Women's Health Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Women's Health Drugs Production Mode & Process
- 8.2 Women's Health Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Women's Health Drugs Distributors
- 8.2.3 Women's Health Drugs Customers
9 Global Women's Health Drugs Analyzing Market Dynamics
- 9.1 Women's Health Drugs Industry Trends
- 9.2 Women's Health Drugs Industry Drivers
- 9.3 Women's Health Drugs Industry Opportunities and Challenges
- 9.4 Women's Health Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst